Comparative Study of T-cell Responses in Oral Cancer Patients
Author Information
Author(s): Kobayashi Jun-ichi, Torigoe Toshihiko, Hirohashi Yoshihiko, Idenoue Satomi, Miyazaki Akihiro, Yamaguchi Akira, Hiratsuka Hiroyoshi, Sato Noriyuki
Primary Institution: Sapporo Medical University School of Medicine
Hypothesis
The study aims to compare the immunogenicity of two HLA-A24-restricted T-cell epitopes derived from survivin and its splice variant in oral cancer patients.
Conclusion
Both survivin-2B80-88 and C58 peptides have comparable potency in inducing cytotoxic T-lymphocytes in oral cancer patients.
Supporting Evidence
- Survivin-2B80-88 peptide-specific CTLs were induced from four patients.
- C58 peptide-specific CTLs were induced from three out of eight patients with over stage II progression.
- CTL induction failed from a healthy volunteer and all four patients with cancer stage I.
Takeaway
The study found that two different pieces of a protein called survivin can help the body's immune system fight oral cancer, and they work similarly well.
Methodology
Peripheral blood lymphocytes from HLA-A24-positive oral cancer patients were stimulated with either Survivin-C58 or Survivin-2B80-88 peptides to induce T-cell responses.
Limitations
The study had a small sample size and did not include patients with early-stage cancer.
Participant Demographics
Participants were HLA-A24-positive oral cancer patients, including both genders and various ages.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website